24.3 billion USD stock-swap merger! Two major North American chemical giants merge—hidden industry pain point: Can the long-standing 'chlor-alkali co-production deadlock' truly be broken?

On June 16, Olin Corporation—the largest chlor-alkali producer in the United States—announced a full-stock merger with Huntsman Corporation. Under the terms, 0.5476 shares of Olin stock will be exchanged for each share of Huntsman stock, valuing the transaction at approximately USD 2.43 billion. Upon completion, Olin shareholders will hold 54.5% of the combined entity, while Huntsman shareholders will hold 45.5%. The merged company will become a North American chemical powerhouse, with combined 2025 revenues estimated at around USD 12.5 billion. Superficially, this appears to be a typical scale-driven consolidation within the chemical industry. However, anyone familiar with the fundamental constraints of the chlor-alkali industry will recognize an almost inevitable industrial logic behind this deal—the answer lies in a production ratio known as the ECU (Electrochemical Unit). The Chlor-Alkali Industry’s Binding Constraint To understand this merger, one must first grasp a core constraint of chlor-alkali production: the ECU ratio (Electrochemical Unit). In chlor-alkali electrolysis, producing 1 ton of chlorine gas (Cl₂) simultaneously yields approximately 1.1 tons of caustic soda (NaOH) and 0.03 tons of hydrogen gas (H₂). These three products are inherently co-produced—you cannot independently adjust output of any single product, nor can you halt chlorine production while continuing to produce caustic soda. This constraint creates substantial commercial pressure in practice. Demand for caustic soda—used in papermaking, textiles, aluminum smelting, and other sectors—is relatively stable; by contrast, chlorine demand is highly concentrated in volatile downstream sectors such as polyvinyl chloride (PVC) and phosgene-based chemicals (e.g., MDI, TDI). When chlorine markets weaken, chlor-alkali producers face a dilemma: either cut production (reducing caustic soda output too, resulting in dual losses), or slash chlorine prices. Yet chlorine is a hazardous gas with limited transport radius and cannot be stored in large quantities over extended periods—it must be consumed locally. Olin Corporation has long struggled under precisely this constraint. A globally recognized vertically integrated chemical producer and distributor—and also a leading U.S. ammunition manufacturer—Olin’s core chemical products include chlorine, caustic soda, vinyl products, epoxy resins, chlorinated organics, bleach, hydrogen, and hydrochloric acid. Its Winchester brand manufactures and sells sporting ammunition, law enforcement ammunition, heavy-duty components, small-caliber military ammunition and accessories, industrial ammunition, and clay targets. As America’s largest chlor-alkali producer, 76% of Olin’s electricity comes from natural gas and hydropower—keeping power costs relatively manageable. Yet persistent difficulties in finding outlets for its chlorine have consistently weighed on profitability. Intensifying global competition in chlorine derivatives has forced Olin, at times, to offload chlorine at steep discounts in the spot market. Screenshot from Olin’s official website Huntsman’s True Identity: The Largest Chlorine Consumer Within the chemical industry, Huntsman is typically positioned as a polyurethane and epoxy resin company. It operates three main business units: Polyurethanes, Advanced Materials, and Functional Products. Yet from the chlor-alkali perspective, Huntsman holds another, more critical identity: one of the world’s leading consumers of chlorine.

Biocytogen’s Q3 Report: Revenue up nearly 50%, non-GAAP net profit up 307%

Recently, investor attention toward the pharmaceutical sector has rebounded, driven by improving prospects for innovative drug overseas expansion, recovery in CRO/CDMO demand, and rising momentum in upstream scientific research services. Following this recent correction, the sector is likely to seek new thematic drivers anchored in solid fundamentals—and Biocytogen’s newly released Q3 report warrants close examination. First, a brief look at financial performance: For the first three quarters of the year, Biocytogen reported revenue of RMB 1.403 billion, up 49.09% year-on-year; net profit attributable to shareholders was RMB 312 million, up 173.77% year-on-year; and non-GAAP net profit attributable to shareholders stood at RMB 235 million, surging 307.62% year-on-year. Gross profit for the first three quarters totaled approximately RMB 1.095 billion, up 55.35% year-on-year, with gross margin climbing to 78.06%. Operating costs rose about 30.40%—significantly slower than revenue growth. R&D expenditure amounted to RMB 442 million, up 41.32% year-on-year, while R&D expense ratio declined to 31.54%. Achieving faster revenue growth without cutting R&D investment—and simultaneously lifting gross margin—reflects exceptionally high-quality growth, effectively amplifying the scale benefits of the company’s technology platform. Excluding fair-value changes and related gains from biological assets and structured deposits, non-GAAP net profit surged 307.62%, further validating the company’s high-quality growth thesis: core profitability is improving rapidly, and earnings quality is strong. From a cash flow perspective, operating cash flow net inflow for the first three quarters totaled RMB 422 million, up 60.54% year-on-year—approximately 1.35 times net profit attributable to shareholders. Meanwhile, net cash outflow from investing activities reached approximately RMB 565 million during the same period, with capital expenditures on long-term assets totaling about RMB 350 million. As of end-September, the company held monetary funds of approximately RMB 909 million. These funding outlays primarily relate to the phased commissioning of its new animal facility in Haimen. Core Business and Growth Potential Biocytogen’s current financial report identifies preclinical services as the most direct growth driver. Although the quarterly report does not disclose segment-level details, publicly available information indicates that as innovative drug development expands into complex molecules—including bispecific and multispecific antibodies—demand for advanced animal models and pharmacological/pharmacodynamic evaluation has intensified.

Olin posts Q3 beat as gains in chlor-alkali, vinyls offset weak epoxy

41 mins ago

Olin Corp reported Q3 adjusted EBITDA of $191 million, beating estimates as chlor-alkali and vinyls gains offset epoxy weakness. Forecasts indicate Q4 EBITDA of $80-$100 million amidst rising feedstock costs and planned price increases.

chemweek

2026-10-31

Olin posts Q3 beat as gains in chlor-alkali, vinyls offset weak epoxy

Olin posts Q3 beat as gains in chlor-alkali, vinyls offset weak epoxy

FAQ